Altimmune (NASDAQ:ALT - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01, Zacks reports. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%.
NASDAQ ALT traded up $0.46 on Thursday, reaching $6.40. 3,819,971 shares of the stock were exchanged, compared to its average volume of 2,188,915. The firm has a market capitalization of $454.81 million, a PE ratio of -4.13 and a beta of 0.19. Altimmune has a one year low of $5.28 and a one year high of $14.84. The company's 50-day simple moving average is $6.92 and its two-hundred day simple moving average is $7.19.
ALT has been the subject of a number of recent research reports. UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They set a "buy" rating and a $26.00 price target for the company. Stifel Nicolaus started coverage on shares of Altimmune in a report on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price objective on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $12.00 target price on shares of Altimmune in a report on Wednesday, February 5th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $20.83.
View Our Latest Research Report on Altimmune
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Altimmune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Altimmune wasn't on the list.
While Altimmune currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.